What will the average number of measles cases be during Trump's term?

**Stage 1 — Blind analysis (ignore market prices)**

*Situation recap and interpretation assumption*: The available reporting clearly shows 2025 was a very high year (2,288 confirmed cases) and 2026 is already above ~2,070 by midyear with reports indicating it will exceed 2,000 again. The event wording in the prompt is ambiguous (a plain text question rather than an explicit threshold). For a grounded, testable analysis I assume the market's "Yes" refers to the average annual measles cases for 2025–2028 being greater than 2,000 (this aligns with the emphasized news signal that cases have exceeded 2,000 in the first two years). If the market used a different threshold, my probability should be reinterpreted accordingly.

*Baseline arithmetic and plausibility*: To have a 4‑year average >2,000 requires a total >8,000 cases across 2025–2028. Known/likely inputs:

- 2025 confirmed = 2,288 (reported). - 2026 is reported as >2,070 midyear and described as a second consecutive year >2,000; conservatively project 2026 year‑end in the ~2,000–2,400 range (I use ~2,200 as a central estimate).

Given those two years, the cumulative for 2025–26 likely sits around 4,400–4,600. That leaves ~3,400–3,600 needed across 2027–28 (≈1,700–1,800 per year) to push the 4‑year average over 2,000. That is materially above pre‑2025 baseline years and requires continued, sustained elevated transmission.

*Epidemiological assessment*: Measles dynamics are strongly driven by population immunity pockets, importations, and public‑health response. Key facts:

- Measles is highly transmissible; a small erosion in vaccination coverage or in outbreak control can produce large increases in cases. - Policy and messaging can change short‑term uptake in some communities, but broad shifts in national coverage typically take multiple years to fully propagate. - Outbreaks can be self‑limiting with rapid, targeted vaccination campaigns; conversely, poor response and spread into multiple under‑vaccinated communities can sustain high incidence through several years.

*Combining arithmetic and epidemiology*: Because 2025–26 already account for roughly half the 8,000 needed, the question hinges on whether 2027–28 see reversion close to historical low levels (hundreds per year) or remain elevated (mid‑thousands). With current signals (anti‑vax messaging from some politicians, reported weak federal response, and officials warning about risking loss of elimination status), sustained elevated transmission is plausible but far from certain. I therefore place an independent probability of **~42%** that the 4‑year average will exceed 2,000.

*Stage 2 — Market calibration (considering current market prices)*

The current market price for Yes is 0.30 (30%). My independent assessment of 42% is materially higher (12 percentage points). Possible reasons for the market price being lower than my estimate:

- **Ambiguity discount**: Market participants may interpret the question/threshold differently (e.g., a higher threshold such as >2,500, or a different averaging rule like median rather than mean), and that ambiguity drives the price down. - **Risk aversion and capitalization of uncertainty**: Traders may overweight the chance that 2027–28 revert to low pre‑outbreak levels due to anticipated catch‑up vaccination campaigns, so they price Yes lower. - **Information lag and conservative priors**: Some traders may be slow to update from the newly available 2025/2026 totals or doubt the accuracy/timeliness of early 2026 reports; they may anchor to the long era of elimination and hence underprice sustained resurgence risk. - **Liquidity and crowding**: The market has substantial volume (~148k contracts), but positions might be driven by hedging or institutional flows that compress prices away from my epidemiological view.

Given these considerations, I see the market at 30% as *somewhat underpriced* versus my 42% view, unless the market is using a different threshold or additional information not in the news summary (for example, private intel on strong planned federal interventions, sudden major increases in routine vaccination coverage nationwide, or a definition that requires >2,000 average *and* loss of elimination). If the threshold is indeed >2,000 average, the 30% price looks too low and offers upside from my perspective; if the threshold is higher or wording stricter, the market price could be rational.

*Bottom line*: Independent (blind) assessment = 42% that the 2025–2028 average annual measles cases exceeds 2,000. Market price = 30% → market may be underpricing continued transmission risk, but the gap may partly reflect question/threshold ambiguity or tail‑risk hedging by traders.